Abdala N, Stephens PC, Griffith BP, Heimer R. Survival of HIV-1 in syringes. J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Jan 1;20(1):73-80.

Abraham JL, Brambilla C. Particle size for differentiation between inhalation and injection pulmonary talcosis. Environ Res. févr 1980;21(1):94‑6.

Crofts N, Caruana S, Bowden S, Kerger M. Minimising Harm From Hepatitis C Virus Needs Better Strategies. BMJ. 2000;321(7265):899.

Debrus M. Impact de nouveaux outils sur les risques de l’injection. Gestion des risques liés au saignement après l’injection, prévention des risques de partage accidentel ou de confusion. OFDT; 2008.

Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. déc 2017;5(12):e1192‑207. Del Giudice P. Cutaneous complications of intravenous drug abuse. Br J Dermatol. janv 2004;150(1):1‑10.

Doerrbecker J, Behrendt P, Mateu-Gelabert P, Ciesek S, Riebesehl N, Wilhelm C, et al. Transmission of Hepatitis C Virus Among People Who Inject Drugs: Viral Stability and Association With Drug Preparation Equipment. J Infect Dis. 15 janv 2013;207(2):281‑7.

Emmanuel F, Archibald C, Razaque A, Sandstrom P. Factors Associated With an Explosive HIV Epidemic Among Injecting Drug Users in Sargodha, Pakistan. JAIDS J Acquir Immune Defic Syndr. mai 2009;51(1):85‑90.

Gordon RJ. Bacterial Infections in Drug Users. N Engl J Med. 2005;353:1945‑54. Hagan H, Thiede H, Weiss S. N. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health. janv 2001;91(1):42‑6.

Hind CR. Pulmonary complications of intravenous drug misuse. 2. Infective and HIV related complications. Thorax. 1 déc 1990;45(12):957‑61.

Jacka B, Larney S, Degenhardt L, Janjua N, Høj S, Krajden M, et al. Prevalence of Injecting Drug Use and Coverage of Interventions to Prevent HIV and Hepatitis C Virus Infection Among People Who Inject Drugs in Canada. Am J Public Health. janv 2020;110(1):45‑50.

Keijzer L, Imbert E, Gabelli N. Utilisation du Stérifilt selon les produits injectés. 2010; Lamb D, Roberts G. Starch and talc emboli in drug addicts’ lungs. J Clin Pathol. 1 oct 1972;25(10):876‑81.

Latkin CA, Kuramoto SJ, Davey-Rothwell MA, Tobin KE. Social Norms, Social Networks, and HIV Risk Behavior Among Injection Drug Users. AIDS Behav. oct 2010;14(5):1159‑68.

McCoy CB, Metsch LR, Chitwood DD, Shapshak P, Comerford ST. Parenteral transmission of HIV among injection drug users: assessing the frequency of multiperson use of needles, syringes, cookers, cotton, and water. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18 Suppl 1:S25-9.

Mezaache S, Briand-Madrid L, Laporte V, Mora M, Moudachirou K, Rojas Castro D, et al. Correlates of Self-Reported Cotton Fever Experience among People Who Inject Opioids. Subst Use Misuse. 1 avr 2020;55(6):1021‑7.

Milroy CM, Parai JL. The histopathology of drugs of abuse: Histopathology of drugs of abuse. Histopathology. oct 2011;59(4):579‑93.

Needle RH, Coyle S, Cesari H, Trotter R, Clatts M, Koester S, Price L, McLellan E, Finlinson A, Bluthenthal RN, Pierce T, Johnson J, Jones TS, Williams M. HIV risk behaviors associated with the injection process: multiperson use of drug injection equipment and paraphernalia in injection drug user networks. Subst Use Misuse. 1998 Oct;33(12):2403-23.

Nguyen VT, Chan ES, Chou S-HS, Godwin JD, Fligner CL, Schmidt RA, et al. Pulmonary effects of i.v. injection of crushed oral tablets: « excipient lung disease ». AJR Am J Roentgenol. nov 2014;203(5):W506-515.
Pouget ER, Hagan H, Des Jarlais DC. Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment: Hepatitis C incidence meta-analysis. Addiction. juin 2012;107(6):1057‑65.

Roux P, Carrieri MP, Keijzer L, Dasgupta N. Reducing harm from injecting pharmaceutical tablet or capsule material by injecting drug users: Microfilters for injecting drug users. Drug Alcohol Rev. mai 2011;30(3):287‑90.Scott J. Safety, Risks and Outcomes from the Use of Injecting Paraphernalia. :117.

Shah SM, Shapshak P, Rivers JE, Stewart RV, Weatherby NL, Xin KQ, Page JB, Chitwood DD, Mash DC, Vlahov D, McCoy CB. Detection of HIV-1 DNA in needle/syringes, paraphernalia, and washes from shooting galleries in Miami: a preliminary laboratory report. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Mar 1;11(3):301-6.

Song H, Li J, Shi S, Yan L, Zhuang H, Li K. Thermal stability and inactivation of hepatitis C virus grown in cell culture. Virol J. 2010;7(1):40.

Spijkerman IJB, van Amejiden EJC, Mientjes GHC, Coutinho RA, van den Hoek A. Human Immunodeficiency Virus Infection and Other Risk Factors for Skin Abscesses and Endocarditis among Injection Drug Users. J Clin Epidemiol. 1996;49(10):1149‑54.

Strike C, Buchman DZ, Callaghan RC, Wender C, Anstice S, Lester B, et al. Giving away used injection equipment: missed prevention message? Harm Reduct J. 2010;7(1):2.

Thorpe LE. Risk of Hepatitis C Virus Infection among Young Adult Injection Drug Users Who Share Injection Equipment. Am J Epidemiol. 1 avr 2002;155(7):645‑53.

Vlahov D, Sullivan M, Astemborski J, Nelson KE. Bacterial Infections and Skin Cleaning Prior to Injection among Intravenous Drug Users. Public Health Rep 1974-. 1992;107(5):595‑8.

Wilson LE, Thomas DL, Astemborski J, Freedman TL, Vlahov D. Prospective Study of Infective Endocarditis among Injection Drug Users. J Infect Dis. 15 juin 2002;185(12):1761‑6.